Introduction
Obesity, central adiposity, dyslipidaemia (hypertriglyceridaemia and a low level of high-density lipoprotein (HDL) cholesterol) and abnormal glucose metabolism are associated with insulin resistance and tend to cluster in the same individuals, especially in hypertensives. [1] [2] [3] [4] [5] [6] The treatment of hypertension with pharmacological agents does not necessarily decrease the metabolic cardiovascular risks of hypertensive patients. 7 The use of high dose thiazides and beta-blockers may even exacerbate an underlying insulin resistance and thereby Correspondence: Dr M Vanhala, Pieksämäki District Health Centre, Seunalantie 1, 76850 Naarajärvi, Finland Received 22 April 1997; revised 29 January 1998; accepted 11 February 1998 normotensive control group of 177 men and women aged 40 and 45 years in the City of Tampere. Main outcome measures: Hyperinsulinaemia defined by using two different cut-off points of the fasting plasma insulin (у13.0 mU/l and у18.0 mU/l). Results: Hyperinsulinaemia у13.0 mU/l was present in 45% of hypertensive men and in 25% of hypertensive women. The sex difference was statistically significant (P Ͻ 0.01). The corresponding rates of hyperinsulinaemia у18.0 mU/l were 18% and 16%. The sensitivity of the test for hyperinsulinaemia у13.0 mU/l was 77% and specificity 73% in men, and 100% and 70% in women. The corresponding figures for hyperinsulinaemia у18.0 mU/l were 94% and 60% in men, and 100% and 63% in women. Conclusion: Our results suggest that hyperinsulinaemia/insulin resistance in hypertensives becomes identifiable by using simple measurements of BMI, WHR, serum triglycerides and HDL cholesterol as well as the oral glucose tolerance test as means.
have unfavourable effects on lipid and glucose metabolism. 8, 9 To improve the treatment outcome of hypertension at the population level it would be of crucial importance to identify the insulin-resistant hypertensive subjects 10 in clinical practice in order to optimise their pharmacological and non-pharmacological treatment with respect to metabolic abnormalities.
Several epidemiological studies have shown that the level of fasting plasma insulin can be used as a marker for insulin resistance in subjects without non-insulin-dependent diabetes (NIDDM). 11, 12 Since the measurement of fasting insulin, however, is not a routine laboratory test in daily practice, there is a need for an 'opportunistic' test for recognising hyperinsulinaemia without it. This would be especially important in the case of subjects with hypertension.
We screened subjects of four middle-aged age 464 groups in Pieksämäki town, Finland for hypertension, and examined the possibility of identifying the hyperinsulinaemia hypertensives with the help of the five following markers: (1) obesity; (2) central adiposity; (3) hypertriglyceridaemia; (4) low level of HDL cholesterol; and (5) impaired glucose tolerance (IGT). A normotensive control population of 177 subjects was examined in the City of Tampere, Finland.
Subjects and methods
The target population consisted of 1172 subjects in four age groups in Pieksämäki, a town with a total of 15 000 inhabitants in Finland. Subjects born in 1942 (n = 164), 1947 (n = 357), 1952 (n = 345) and 1957 (n = 306) were included in the study. The sample was drawn from an updated census register and invited by letter for screening which was carried out by two trained nurses between March 1993 and June 1994. Subjects with NIDDM were excluded. A control population of 177 normotensive subjects was selected randomly from the voluntary participants in the health check-ups, which are arranged annually for all inhabitants aged 40 and 45 years in the City of Tampere, Finland. Subjects with NIDDM were excluded. This part of the study was conducted in 1994. Blood pressure (BP) was measured after a 15-min rest in the sitting position.
13 Two readings at 2-min intervals were obtained and the second one was used. An appropriate large cuff was used for obese subjects. Hypertension was defined to be present in subjects who had a systolic BP of 160 mm Hg or more and/or a diastolic BP of 95 mm Hg or more, or were on medication for hypertension. The use of anti-hypertensive drugs was obtained with direct questioning.
For anthropometric measurements, the subjects were examined in light clothing. Height was measured to the nearest cm, weight to the nearest 0.1 kg. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m 2 ). Obesity was defined as BMI у30 kg/m 2 . Waist and hip circumferences were measured to the nearest cm with a calibrated soft tape with the subject standing. Waist was defined as the smallest girth midway between the lowest rib margin and the iliac crest. Hip was defined as the circumference at the level of the greater trochanters and the waist-to-hip ratio (WHR) was calculated. Central adiposity was defined to be present in men with WHR у1.00 and in women with WHR у0.88. These cut-off points represent the highest quartile of the distribution among subjects aged 41 and 46 years in the study population.
Serum cholesterol and triglycerides were measured from fresh serum samples drawn after an overnight fast using enzymatic colorimetric methods (CHOD-PAP, GPO-PAP: Boehringer Mannheim GmbH, Germany). Serum HDL cholesterol was measured with the same method after precipitation of low-density lipoprotein and very low-density lipoprotein cholesterol by phosphotungstic acid and magnesium. Hypertriglyceridaemia was defined as у1.70 mmol/l and a low level of HDL cholesterol as Ͻ1.0 mmol/l in men and Ͻ1.20 mmol/l in women. 14, 15 Plasma for the determination of fasting insulin was separted by centrifugation. The samples were immediately frozen at −20°C. Insulin was determined by the Phadeseph Insulin RIA, 100 method (Pharmacia Diagnostics AB, Uppsala, Sweden).
The oral glucose tolerance test was performed as recommended by the WHO (75 g of glucose). Glucose concentrations were measured by an automated colorimetric method (Peridochrom Glucose GOD-PAP: Boehringer, Germany). IGT was defined according to the WHO recommendations. 16 The test for hyperinsulinaemia consisted of the following five markers: (1) obesity; (2) central adiposity; (3) hypertriglyceridaemia; (4) a low level of HDL cholesterol; and (5) abnormal glucose metabolism. A test result was defined to be positive if any two or more of the five markers were simultaneously present in the same individual.
Statistical methods
The statistical analyses were performed with the SPSS/PC+ statistical software. The significance of the differences between the means of variables were analysed by using the Student's t-test for independent samples. The association between the fasting plasma insulin (log transformed) and the number of other markers for insulin resistance was calculated by using ANOVA. Chi-squared methods were used to compare the categorical variables between the groups. The sensitivity, specificity and positive and negative predictive values calculations were based on a 2×2 table.
Results
After exclusion of two pregnant women, three foreigners and 19 individuals who could not be contacted, the size of the study population was 1148 subjects. Of these, 841 (73%) subjects participated in the study. Hypertension was present in 100/394 (25%) men and in 61/447 (14%) women. After the exclusion of NIDDM paients (four men [4%] and five women [8%]), the final study population consisted of 152 hypertensive subjects (96 men and 56 women). Of these, 78 (51%) were on anti-hypertensive medication. Beta-blockers, diuretics, or both were being used by 40 (51%) drug-treated subjects.
In 1994 in the city of Tampere, 4386 (80%) of the 5480 invited inhabitants aged 40 and 45 years participated in the health check-ups. The control population included 177 normotensive subjects (85 men and 92 women). After exclusion of one man and two women with NIDDM (1.7%), the final control population included 174 subjects.
All the examined markers of insulin resistance (obesity, central adiposity, dyslipidaemia, and IGT) were more frequently present in the hypertensives, as compared to the normotensive controls. Hyperinsulinaemia у13.0 mU/l was present in 43/95 (45%) hypertensive men and in 14/57 (25%) hypertensive women, the difference between sexes being statistically significant (P Ͻ 0.01). The prevalence of hyper- insulinaemia у13.0 mU/l was about three-fold higher in the hypertensives, as compared to the normotensive controls (Table 1) . None of the measured five markers of hyperinsulinaemia was found to be present in 44/152 (29%) subjects with hypertension, and in 95/174 (55%) normotensive controls. In both groups, the higher the number of markers for hyperinsulinaemia per subject, the higher the level of the fasting plasma insulin. Table 2 shows the level of fasting plasma insulin according to the number of markers for hyperinsulinaemia which simultaneously were present in the same individual.
The test result was positive (at least two markers were simultaneously present) for 47/95 (49%) hypertensive men and 27/57 (47%) hypertensive women. In the control group, the test result was positive for 16/84 (19%) men and for 16/90 (18%) women. Among the hypertensives with a positive test result, the prevalence of hyperinsulinaemia у13.0 mU/l was 70% for men and 52% for women (Table 3) .
In the hypertensive men, the sensitivity of the test for hyperinsulinaemia у13.0 mU/l was 77%, the specificity 73%, the positive predictive value (PPV) 70% and the negative predictive value (NPV) 79%. The corresponding figures for the hypertensive women were 100%, 70%, 52%, and 100%. The sexspecific validity of the test according to the number of the present markers for hyperinsulinaemia у13.0 mU/l, and for hyperinsulinaemia у18.0 mU/l is shown in Table 4 .
Among the subjects on anti-hypertensive drugs, the sensitivity of the test was 79% and the specificity 77%. The corresponding figures in the nontreated hypertensives were 87% and 67%.
Discussion
Since some anti-hypertensives have an adverse effect on insulin resistance, there has been a need of means for the detection of hyperinsulinaemia/insulin resistant hypertensives in daily clinical practice. 6, [8] [9] [10] 15 Our results suggest that by using simple anthropomethric and biochemical markers as a test, three-quarters of hypertensive subjects with hyperinsulinaemia у13.0 mU/l and almost all with hyperinsulinaemia у18.0 mU/l become identifiable, and that the test is feasible for both drug-treated and non-treated hypertensives. The weakness in our study is its cross-sectional nature and that the definition of hypertension was based on measurements being made on a single visit. This, of course may lead to an overestimation of hypertension. On the 466 (10) 44 (7) 4 ( other hand, we used a normotensive control group in proving the high relative prevalence of different disorders in the hypertensives as compared to the normotensives. It has been recommended that the level of fasting plasma insulin should be used as a marker of insulin resistance in epidemiological studies. 12 Since the biological variability of fasting plasma insulin is great, 2, 11, 12 there is not any generally accepted definition for hyperinsulinaemia available. In our study, the definition of hyperinsulinaemia was based on two different cut-off levels of the fasting plasma insulin. The first, у13.0 mU/l, has been shown to be the level of the fasting plasma insulin at which more than 74% of the subjects with normal or abnormal glucose metabolism were insulin-resistant (measured by the euglycaemic hyperinsulinaemic clamp technique), and the second, у18.0 mU/l, the level of insulin at which all subjects were insulin resistant. 12 We used the same method and the same laboratory as in the study mentioned above.
Our results also show that the higher the number of markers for insulin resistance clustering in the same individual, the higher was the mean level of the fasting plasma insulin. This finding is in line with some other studies showing that the insulinresistant hypertensives have a significantly higher degree of clustering of metabolic abnormalities than do the non-insulin-resistant hypertensives. 17 Furthermore, when two of the five markers clustered in the same hypertensive individual, the mean fasting plasma insulin exceeded 13.0 mU/l, the level at which three quartiles of subjects have been shown to be insulin resistant. Based on this finding, the cluster of at least two examined markers was defined as a positive test result for hyperinsulinaemia among the hypertensives.
The prevalence of hyperinsulinaemia у13.0 mU/l and hyperinsulinaemia у18.0 mU/l were statistically significantly higher in the hypertensives, as compared to the normotensive controls. In both groups, the rates of hyperinsulinaemia were also higher in men than in women. This result gives indirect evidence that the hypertensives are, as a group, more often insulin resistant than the normotensive controls. This also shows that men are more often hyperinsulinaemic and thereby possibly more insulin resistant than women. The difference between the sexes might be explained by environmental factors, such as the distribution of fat and hormonal effects, which can modify insulin resistance in subjects of these age groups more in men than in women. 18, 19 Among the hypertensives, the sensitivity of the presented test for hyperinsulinaemia у13.0 mU/l was 77% for men and 100% for women. The specificity of 70-73% for the test showed that about a quartile of the subjects without hyperinsulinaemia у13.0 mU/l were misdiagnosed.
Furthermore, the sensitivity for hyperinsulinaemia у18.0 mU/l was even better, being 94% for men and 100% for women. In this study, the test overlooked only 10 (18%) of the 57 hypertensive subjects with hyperinsulinaemia у13.0 mU/l and one (4%) of the 26 hypertensive subjects with hyperinsulinaemia у18.0 mU/l. Since the mean level of fasting plasma insulin increased with the increase of the number of markers clustering in the same individual, this finding gives evidence to suggest that the higher the number of markers in the cluster, the better the sensitivity of the test. Therefore, the presented test identifies better the hypertensive subjects with a higher level of insulin than those with a lower level of insulin.
PPV of the test for hyperinsulinaemia у13.0 mU/l was 70% for the hypertensive men and 52% for women. This means that about two-thirds of subjects with a positive test result really had hyperinsulinaemia у13.0 mU/l. The proportion of false positive test results is not so important if we consider this result from the clinical viewpoint. Since the subjects with a positive test result, however, had a cluster of at least two other cardiovascular risk factors in addition to the hypertension, they need attention and should be a target for preventive measures against coronary heart disease. 20 In clinical practice, measurements of BMI, WHR and serum lipids and as well as the oral glucose tolerance test should be part of the treatment of hypertension. If a hypertensive has a negative test result, the possibility of more severe hyperinsulinaemia is minimal. If he/she has two of the five mentioned markers for hyperinsulinaemia, the physician should be careful in prescribing diuretics or betablocking agents for the treatment of hypertension. If the hypertensive patient has three or more markers for hyperinsulinaemia, it would be better to avoid the use of high-dose diuretics and beta-blocking agents for hypertension, if there is not some other important reason for the use of these agents (coronary heart, disease, etc). 21 The presented opportunistic test for hyperinsulinaemia consisting of the five presented markers and being positive if the hypertensive simultaneously has at least two out of the five, is feasible to be conducted in the clinical practice.
